Advanced search×

Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas.

Daniel D Zips, Katja K Le, Ala A Yaromina, Annegret A Dörfler, Wolfgang W Eicheler, Xuanjing X Zhou, Peter P Geyer, Frank F Hilberg, and Michael M Baumann

Radiother Oncol 92(3):405-10 (2009) PMID 19409639

To test the effect of BIBF 1120, a novel small molecule inhibitor of multiple angiogenic receptor tyrosine kinases, on the hypoxia and radiation response of tumours.

Copyright © 2009 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.radonc.2009.04.006
Version: za2963e q8za7 q8zb2 q8zc8 q8zdd q8zee q8zf5 q8zg5
Buy PDF

Similar articles you may find interesting…

  1. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
    Kaori Sakuishi, Lionel Apetoh, ... Ana C Anderson

    J Exp Med 208(6):1331 (2011)

    Buy PDF
  2. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-s...
    Gerald J GJ Roth, Armin A Heckel, ... Frank F Hilberg

    J Med Chem 52(14):4466-80 (2009) PMID 19522465

    Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a new treatment modality in oncology. Preclinical findings suggest that blockade of additional pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor recepto...
    Buy PDF
  3. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.
    Martin M Kropff, Joachim J Kienast, ... Gerd G Munzert

    Anticancer Res 29(10):4233-8 (2009) PMID 19846979

    Two DLTs (200 and 250 mg) occurred due to increased gamma-glutamyltransferase levels (CTC grade 3). The 250 mg dose was well tolerated; no dose escalation beyond 250 mg was made. The most common adverse events included diarrhoea, nausea and vomiting. No detectable deviation from dose linear PKs was...
    Buy PDF